A therapeutic role for matrix metalloproteinase inhibitors in lung diseases? Source: Eur Respir J 2011; 38: 1200-1214 Year: 2011
Detrimental role for matrix metalloprotease-1 in the pathogenesis of pulmonary fibrosis Source: International Congress 2017 – Novel pro- and anti-fibrotic mechanisms in pulmonary fibrosis Year: 2017
Role of matrix metalloproteinases in progression of idiopathic pulmonary fibrosis Source: Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease Year: 2010
Matrix metalloproteinases (MMPs) and angiogenesis in lung tissue remodeling in different variants of idiopathic interstitial pneumonia (IIP) Source: Eur Respir J 2007; 30: Suppl. 51, 137s Year: 2007
The prognostic role of matrix metalloproteinase-7 in scleroderma-associated interstitial lung disease Source: Eur Respir J, 58 (6) 2101560; 10.1183/13993003.01560-2021 Year: 2021
The role of pathological angiogenesis in the pathogenesis of the chronic inflammatory lung diseases Source: Annual Congress 2005 - Update on the role of angiogenesis in the pathogenesis and treatment of lung diseases Year: 2005
The role of matrix metalloproteinases in cystic fibrosis lung disease Source: Eur Respir J 2011; 38: 721-727 Year: 2011
Matrix metalloproteinases and tissue inhibitor of metalloproteinase-1 in sarcoidosis and IPF Source: Eur Respir J 2002; 20: 1220-1227 Year: 2002
The pathomechanistic role of autophagy in lung fibrosis Source: International Congress 2017 – Interstitial lung diseases (ILDs): novel pathogenetic pathways Year: 2017
MMPs are regulatory enzymes in pathways of inflammatory disorders, tissue injury, malignancies and remodelling of the lung Source: Eur Respir J 2011; 37: 12-14 Year: 2011
MMP expression and abnormal lung permeability are important determinants of outcome in IPF Source: Eur Respir J 2009; 33: 77-84 Year: 2009
Matrix metalloproteinase (MMP)-2 production by fibroblasts and mast cells: the role in pulmonary fibrosis Source: Eur Respir J 2004; 24: Suppl. 48, 455s Year: 2004
Regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases expression in the bronchial secretions of asthmatics and COPD Source: Eur Respir J 2002; 20: Suppl. 38, 92s Year: 2002
PP216 – Glucocorticoids exacerbate TGFß1 mediated fibrotic signalling in lung fibroblasts by inhibition of metalloproteinase expression and activity Source: ERS Lung Science Conference 2021 Year: 2021
Remodelling of extracellular matrix (ECM) differs between tumor centre and invasion front in human non-small cell lung cancer: immunohistochemistry and morphometry of matrix proteins (MP), matrix metalloproteinases (MMPs), and tissue inhibitors of MMPs (T Source: Annual Congress 2008 - Novel trends in functional genomics and molecular pathology of neoplastic and non-neoplastic lung diseases Year: 2008
Investigation of the citrullination pathway in the pathogenesis of fibrotic lung disorders Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012
The role of CX3CL1 and ADAM17 in pathogenesis of diffuse parenchymal lung diseases Source: Virtual Congress 2021 – Translational and other aspects of idiopathic interstitial pneumonia Year: 2021